Is your decision to treat with hypofractionated radiation impacted by histology, ie lobular vs ductal cancers?

Our present approach is to treat all patients (ductal and lobular) and all phenotype with hypofractionation (where we treat breast without RNI) followed by boost. If we feel a patient would benefit from a higher dose we would increase the boost dose but still do hypofractionation for the breast

According to the most recent ASTRO whole breast fractionation guideline published in PRO in 2018, hypofractionation may be employed independent of subtype, ER, PR, HER2 or grade and therefore would be acceptable with lobular and other typical breast histologies. They do note, with a low level of evi...